Q-omics provides the consensus-scored OPN4 profile across patient tissues and cancer cell-line models. OPN4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, OPN4 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, OPN4 RNA expression shows 10,858 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, COAD, and GBM as cancer lineages where OPN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OPN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OPN4 survival associations across molecular data types. OPN4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OPN4 RNA expression–survival associations across cancer types. High OPN4 expression shows unfavorable associations in BRCA, SKCM, KIRC, CESC and KIRP, but favorable associations in HNSC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for OPN4 RNA expression.
This table summarizes OPN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for OPN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OPN4 shows lower tumor expression in COAD and BRCA and higher tumor expression in KIRC, KICH, LIHC and LUAD. The COAD box plot shows higher OPN4 RNA expression in normal versus tumor tissue (log2 FC = −0.244, t-test p < 0.001).
This table shows molecular features associated with OPN4 in patient tissues and cancer cell lines. In patient samples, OPN4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, OPN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
